STAT3 oligonucleotide inhibits tumor angiogenesis in preclinical models of squamous cell carcinoma

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Klein, Jonah D ^a   Sano, Daisuke ^b   Sen, Malabika ^a   Myers, Jeffrey N ^c   Grandis, Jennifer R ^a   Kim, Seungwon ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CISPLATIN; SMALL INTERFERING RNA; STAT1 PROTEIN; STAT3 DECOY OLIGONUCLEOTIDE; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA;

ANIMALS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; HEAD AND NECK NEOPLASMS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDES; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896742116     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081819     Document Type: Article

References (36)

1. Leeman RJ, Lui VW, Grandis JR (2006) STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther 6: 231-241. (Pubitemid 43344743)
2. Van Tubergen E, Vander Broek R, Lee J, Wolf G, Carey T, et al. (2011) Tristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma. Cancer.
3. Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, et al. (2008) Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 113: 750-757.
4. Zhang X, Liu P, Zhang B, Wang A, Yang M (2010) Role of STAT3 decoy oligodeoxynucleotides on cell invasion and chemosensitivity in human epithelial ovarian cancer cells. Cancer Genet Cytogenet 197: 46-53.
5. Gu J, Li G, Sun T, Su Y, Zhang X, et al. (2008) Blockage of the STAT3 signaling pathway with a decoy oligonucleotide suppresses growth of human malignant glioma cells. J Neurooncol 89: 9-17.
6. Sun X, Zhang J, Wang L, Tian Z (2008) Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett 262: 201-213.
7. Zhang X, Zhang J, Wei H, Tian Z (2007) STAT3-decoy oligodeoxynucleotide inhibits the growth of human lung cancer via down-regulating its target genes. Oncol Rep 17: 1377-1382.
8. Sun Z, Yao Z, Liu S, Tang H, Yan X (2006) An oligonucleotide decoy for Stat3 activates the immune response of macrophages to breast cancer. Immunobiology 211: 199-209. (Pubitemid 43337760)
9. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, et al. (2003) Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A 100: 4138-4143. (Pubitemid 36418170)
10. Sen M, Thomas S, Ly D, Rapireddy S, Grandis J (2010) Development of a transcription factor decoy for efficient systemic administration in head and neck cancer. American Association for Cancer Research Annual Meeting.
11. Sen M, Thomas S, Rapireddy S, Yeh J, Shi H, et al. Development of a STAT3 Decoy for Systemic Administration in Head and Neck Cancer; 2010; Arlington, VA.
12. Sen M, Tosca PJ, Zwayer C, Ryan MJ, Johnson JD, et al. (2009) Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol 63: 983-995.
13. Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, et al. (2012) First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov 2: 694-705.
14. Ni CW, Hsieh HJ, Chao YJ, Wang DL (2004) Interleukin-6-induced JAK2/STAT3 signaling pathway in endothelial cells is suppressed by hemodynamic flow. Am J Physiol Cell Physiol 287: C771-780. (Pubitemid 39095864)
15. Bartoli M, Gu X, Tsai NT, Venema RC, Brooks SE, et al. (2000) Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. J Biol Chem 275: 33189-33192.
16. Bartoli M, Platt D, Lemtalsi T, Gu X, Brooks SE, et al. (2003) VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J 17: 1562-1564.
17. Duan W, Yang Y, Yi W, Yan J, Liang Z, et al. (2013) New Role of JAK2/STAT3 Signaling in Endothelial Cell Oxidative Stress Injury and Protective Effect of Melatonin. PLoS One 8: e57941.
18. Kano A, Wolfgang MJ, Gao Q, Jacoby J, Chai GX, et al. (2003) Endothelial cells require STAT3 for protection against endotoxin-induced inflammation. J Exp Med 198: 1517-1525. (Pubitemid 37467166)
19. Yigitbasi OG, Younes MN, Doan D, Jasser SA, Schiff BA, et al. (2004) Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res 64: 7977-7984. (Pubitemid 39446932)
20. Nor JE, Peters MC, Christensen JB, Sutorik MM, Linn S, et al. (2001) Engineering and characterization of functional human microvessels in immunodeficient mice. Lab Invest 81: 453-463. (Pubitemid 32298790)
21. Polverini PJ, Nor JE, Peters MC, Mooney DJ (2003) Growth of human blood vessels in severe combined immunodeficient mice. A new in vivo model system of angiogenesis. Methods Mol Med 78: 161-177.
22. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, et al. (2000) Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 97: 4227-4232. (Pubitemid 30226115)
23. Lui VW, Boehm AL, Koppikar P, Leeman RJ, Johnson D, et al. (2007) Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1. Mol Pharmacol 71: 1435-1443. (Pubitemid 46658696)
24. Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, et al. (1996) Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 272: 719-722.
25. Xi S, Gooding WE, Grandis JR (2005) In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 24: 970-979. (Pubitemid 40313874)
26. Niu G, Wright KL, Huang M, Song L, Haura E, et al. (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008. (Pubitemid 34270888)
27. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309. (Pubitemid 20066716)
28. Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, et al. (2003) Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 63: 2948-2956. (Pubitemid 36667168)
29. Nielsen M, Kaltoft K, Nordahl M, Ropke C, Geisler C, et al. (1997) Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci U S A 94: 6764-6769. (Pubitemid 27281938)
30. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, et al. (2009) The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16: 487-497.
31. Yahata Y, Shirakata Y, Tokumaru S, Yamasaki K, Sayama K, et al. (2003) Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. J Biol Chem 278: 40026-40031. (Pubitemid 37248568)
32. Schaefer LK, Ren Z, Fuller GN, Schaefer TS (2002) Constitutive activation of Stat3alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene 21: 2058-2065. (Pubitemid 34270894)
33. Battle TE, Lynch RA, Frank DA (2006) Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res 66: 3649-3657.
34. Huang S, Bucana CD, Van Arsdall M, Fidler IJ (2002) Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene 21: 2504-2512. (Pubitemid 34438103)
35. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, et al. (2009) Erlotinib and bevacizumab in patients with recurrent or metastatic squamouscell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 10: 247-257.
36. Sano D, Kawakami M, Fujita K, Kimura M, Yamashita Y, et al. (2007) Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncol Rep 17: 289-295.